TIME Magazine: TIME 100: Daniel Vasella


	NATION \| WORLD \| BUSINESS \| ARTS \| PHOTOS \| CURRENT ISSUE

Daniel Vasella

Builders & Titans
	Lee Scott Carly Fiorina Abigail Johnson David Neeleman Rupert Murdoch Lindsay Owen-Jones Howard Schultz Azim Premji Warren Buffett Michael Dell Al-Jazeera Lord John Browne Hiroshi Okuda / Fujio Cho Sergey Brin / Larry Page Bernard Arnault Sepp Blatter Belinda Stronach Meg Whitman Daniel Vasella Steve Jobs
	Leaders & Revolutionaries Artists & Entertainers Scientists & Thinkers Heroes & Icons Introduction Essay FROM THE ARCHIVE: Builders & Titans from 1900-1999

Physician Turned Global CEO

By UNMESH KHER

JASON GROW FOR TIME

FROM THE TIME ARCHIVE

	Drug Lord Fluent in management and cross-cultural p.r., the head of Novartis is the very model of a modern global CEO [7/29/2002]

Heading up a multinational drug firm is a high-wire act. When you aren't struggling to satisfy investors, you're justifying the high cost of your products to consumers. Daniel Vasella, CEO of the Swiss company Novartis, seems to pull off the act effortlessly. Urbane, understated, uncommonly charming, Vasella—a physician by training—speaks three languages fluently and flits easily between the varied social and commercial cultures in which his company operates. He's Swiss and proud of it, but his business sense is quintessentially American.

Vasella, 50, says his first responsibility is to his investors. But in an industry that has plenty of critics, he believes in a credible commitment to ethical practices. Novartis was quick to sign on to the U.N.'s Global Compact, which requires that its corporate signatories commit to the highest environmental, human-rights and labor standards wherever they operate. "He epitomizes a kind of leadership that puts equal emphasis on the social value created by the product and its economic value," notes Rosabeth Kanter, a consultant and professor at Harvard Business School.

Vasella hasn't practiced medicine since he started his business career at the age of 34, but he brings a physician's sensibility to his job. Still, he doesn't run a philanthropy. Thanks to aggressive marketing in the U.S., Novartis' sales surged 19% last year, to nearly $25 billion, as it became the world's fifth largest and fastest-growing of the giant drug firms.

Sept. 27, 1999	Dec. 7, 1998	March 17, 1941

Larger Cover	Larger Cover	Larger Cover